Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | MB | P02144 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14808444 | 0.82 | KMT2A (1.00) | MEN1KMT2ATDP1LMNACYP1A2 | |
| SCHEMBL29056860 | 0.81 | ALDH1A1 (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6516221 | 0.79 | KMT2A (0.73) | MEN1KMT2ATDP1LMNACYP1A2 | |
| SCHEMBL1736253 | 0.79 | MTNR1A (0.55) | MEN1KMT2ATDP1CYP1A2SMN1; SMN2 | |
| SCHEMBL861674 | 0.78 | SMN1; SMN2 (0.84) | MEN1KMT2ATDP1SMN1; SMN2HTT | |
| SCHEMBL5582643 | 0.78 | EPHX2 (0.51) | MEN1KMT2ACYP1A2L3MBTL1CA1 | |
| SCHEMBL171415 | 0.78 | SMN1; SMN2 (0.73) | MEN1KMT2ATDP1LMNACYP1A2 | |
| SCHEMBL27267778 | 0.78 | SMN1; SMN2 (0.73) | MEN1KMT2ATDP1LMNACYP1A2 | |
| SCHEMBL27828678 | 0.78 | CYP17A1 (0.48) | MEN1KMT2ACYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL28226150 | 0.77 | TGM2 (0.65) | KMT2ALMNASMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103110635-A | Histamine H3 receptor antagonist | NOVO NORDISK AS | 2013-05-22 | — | — | CN | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-7977334-B2 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| CN-101218206-A | Histamine H3 receptor antagonists | NOVO NORDISK AS (DK) | 2008-07-09 | — | — | CN | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | PPARA, PPARD, PPARG | MEN1 4667/4885KMT2A 2672/4885TDP1 4316/4885 |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | MEN1 1897/4885KMT2A 4664/4885TDP1 1157/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | MEN1 1897/4885KMT2A 4664/4885TDP1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.